On August 20, Insilico Medicine unveiled a research and development partnership with Byterna Therapeutics, a firm dedicated to advancing cutting-edge RNA-based pharmaceuticals. The collaboration will harness AI technology for precise neoantigen prediction and sequence optimization, combining circular mRNA technology, targeted delivery systems, automated experimental processes, and intelligent manufacturing techniques. Together, they aim to construct a next-generation mRNA AI-driven research and development platform, with the goal of exploring personalized cancer vaccines and related innovative treatment modalities.